Use of psychotropic medication in children and adolescents with autism spectrum disorders

Pediatrics

Volumn 130, Issue SUPPL. 2, 2012, Pages

  Coury, Daniel L ^a   Anagnostou, Evdokia ^b   Manning Courtney, Patricia ^c   Reynolds, Ann ^d   Cole, Lynn ^e   McCoy, Robin ^f   Whitaker, Agnes ^g   Perrin, James M ^h  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF NURSING   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autism spectrum disorders; Medical comorbidity; Psychiatric comorbidity; Psychotropic medications

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ANXIETY; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; AUTISM TREATMENT NETWORK; BIPOLAR DISORDER; CANADA; CHILD; COMORBIDITY; DEMOGRAPHY; DEPRESSION; DSM-IV; ETHNICITY; GASTROINTESTINAL DISEASE; HEALTH CARE ACCESS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; OBSESSIVE COMPULSIVE DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RACE; REGISTER; SCHOOL CHILD; SLEEP DISORDER; UNITED STATES;

ADOLESCENT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; PSYCHOTROPIC DRUGS;

EID: 84868609904     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0900D     Document Type: Article

References (31)

1. Langworthy-Lam KS, Aman MG, Van Bourgondien ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol. 2002;12(4):311-321 (Pubitemid 36169283)
2. Aman MG, Lam KS, Collier-Crespin A. Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J Autism Dev Disord. 2003;33(5):527-534 (Pubitemid 37351601)
3. Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2007;17(3):348-355 (Pubitemid 47067958)
4. Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008;121(3). Available at: www.pediatrics.org/ cgi/content/full/121/3/e441
5. Gerhard T, Chavez B, Olfson M, Crystal S. National patterns in the outpatient pharmacological management of children and adolescents with autism spectrum disorder. J Clin Psychopharmacol. 2009;29(3):307-310
6. Witwer A, Lecavalier L. Treatment incidence and patterns in children and adolescents with autism spectrum disorders. J Child Adolesc Psychopharmacol. 2005;15(4):671-681 (Pubitemid 41434371)
7. Owens JA, Spirito A, McGuinn M. The Children's Sleep Habits Questionnaire (CSHQ): Psychometric properties of a survey instrument for school-aged children. Sleep. 2000;23(8):1043-1051 (Pubitemid 32046173)
8. Goodlin-Jones BL, Sitnick SL, Tang K, Liu J, Anders TF. The Children's Sleep Habits Questionnaire in toddlers and preschool children. J Dev Behav Pediatr. 2008;29(2):82-88 (Pubitemid 351535879)
9. Achenbach T, Rescorla L. Child Behavior Checklist. Burlington, VT: ASEBA; 2000
10. Campbell DB, Buie TM, Winter H, et al. Distinct genetic risk based on association of MET in families with co-occurring autism and gastrointestinal conditions. Pediatrics. 2009;123(3):1018-1024
11. Buie T, Campbell DB, Fuchs GJ III, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: A consensus report. Pediatrics. 2010;125(suppl 1):S1-S18 doi:10.1542/peds.2009-1878C
12. Schreck KA, Mulick JA, Smith AF. Sleep problems as possible predictors of intensified symptoms of autism. Res Dev Disabil. 2004;25(1):57-66 (Pubitemid 38088011)
13. van der Helm E, Gujar N, Walker MP. Sleep deprivation impairs the accurate recognition of human emotions. Sleep. 2010;33(3):335-342
14. Gujar N, McDonald SA, Nishida M, Walker MP. A role for REM sleep in recalibrating the sensitivity of the human brain to specific emotions. Cereb Cortex. 2011;21(1):115-123
15. Mojtabai R, Olfson M. Proportion of anti-depressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood). 2011;30(8):1434-1442
16. Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry. 2010;49(10):1001-1010
17. Mark TL. For what diagnoses are psychotropic medications being prescribed? A nationally representative survey of physicians. CNS Drugs. 2010;24(4):319-326
18. Aman MG, Farmer CA, Hollway J, Arnold LE. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am. 2008;17(4):713-738, vii
19. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266-1274
20. Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry. 2007;61(4):538-544 (Pubitemid 46185343)
21. Jahromi LB, Kasari CL, McCracken JT, et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord. 2009;39(3):395-404
22. Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: A retrospective and prospective effectiveness study. Child Care Health Dev. 2006;32(5):575-583 (Pubitemid 44210096)
23. Murray MJ. Attention-deficit/hyperactivity disorder in the context of autism spectrum disorders. Curr Psychiatry Rep. 2010;12(5):382-388
24. Posey DJ, Erickson CA, Stigler KA, McDougle CJ. The use of selective serotonin reuptake inhibitors in autism and related disorders. J Child Adolesc Psychopharmacol. 2006;16(1-2):181-186
25. Kolevzon A, Mathewson KA, Hollander E. Selective serotonin reuptake inhibitors in autism: A review of efficacy and tolerability. J Clin Psychiatry. 2006;67(3):407-414
26. King BH, Hollander E, Sikich L, et al STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583-590
27. Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010;8(8):CD004677
28. McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry. 2008;69(suppl 4):15-20
29. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162(6):1142-1148 (Pubitemid 40770697)
30. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry. 2005;162(7):1361-1369
31. Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev. 2007;(1):CD005040